- Open Access
SHP1-mediated cell cycle redistribution inhibits radiosensitivity of non-small cell lung cancer
- Rubo Cao†1,
- Qian Ding†1,
- Pindong Li1,
- Jun Xue1,
- Zhenwei Zou1,
- Jing Huang1 and
- Gang Peng1Email author
© Cao et al.; licensee BioMed Central Ltd. 2013
- Received: 29 March 2013
- Accepted: 2 July 2013
- Published: 10 July 2013
Radioresistance is the common cause for radiotherapy failure in non-small cell lung cancer (NSCLC), and the degree of radiosensitivity of tumor cells is different during different cell cycle phases. The objective of the present study was to investigate the effects of cell cycle redistribution in the establishment of radioresistance in NSCLC, as well as the signaling pathway of SH2 containing Tyrosine Phosphatase (SHP1).
A NSCLC subtype cell line, radioresistant A549 (A549S1), was induced by high-dose hypofractionated ionizing radiations. Radiosensitivity-related parameters, cell cycle distribution and expression of cell cycle-related proteins and SHP1 were investigated. siRNA was designed to down-regulate SHP1expression.
Compared with native A549 cells, the proportion of cells in the S phase was increased, and cells in the G0/G1 phase were consequently decreased, however, the proportion of cells in the G2/M phase did not change in A549S1 cells. Moreover, the expression of SHP1, CDK4 and CylinD1 were significantly increased, while p16 was significantly down-regulated in A549S1 cells compared with native A549 cells. Furthermore, inhibition of SHP1 by siRNA increased the radiosensitivity of A549S1 cells, induced a G0/G1 phase arrest, down-regulated CDK4 and CylinD1expressions, and up-regulated p16 expression.
SHP1 decreases the radiosensitivity of NSCLC cells through affecting cell cycle distribution. This finding could unravel the molecular mechanism involved in NSCLC radioresistance.
- Non-small cell lung cancer
- Cell cycle
Lung cancer is one of the malignant tumors with the fastest-growing morbidity and mortality in China. Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer cases, and has a 5-year survival rate of less than 15% . Radiations therapy has been regarded as the main treatment strategy for NSCLC for a long time. However, radioresistance is the key issue limiting the effects of radiations . Due to the presence of tumor cells heterogeneity, malignant cells might exhibit different degrees of radiosensitivity even when they are from the same histological differentiation status. Radioresistant cells can survive to radiotherapy, which in turn induces the local recurrence of NSCLC [3, 4]. Many recent advances in functional imaging and radiations therapy technology, such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), allowed for improved treatments. However, strategies for overcoming the radioresistance-related treatment failure in NSCLC are still largely unknown .
It has been found that the intrinsic radiosensitivity of cells subpopulations present in low- and high-radiosensitive subsets is different. This difference is based on the level of hypoxia, DNA repair capacity, the number of dividing and apoptotic cells and cell cycle phases. Among these, the regulation of cell cycle might play a major role in this process [6, 7].
The biological behavior of NSCLC is closely related to a variety of cellular signal transduction pathways [8–12]. Protein tyrosine kinase (PTK) and protein tyrosine phosphatase (PTP) are two important signals mediating tyrosine phosphorylation and dephosphorylation, respectively. PTK, PTP and their substrates act for signal transduction. Previous studies have shown [13, 14] that multiple tyrosine phosphorylation proteins play a pivotal role during the development of diseases. Indeed, the protein tyrosine phosphatase SHP1 is a key regulator that mediates the level of intracellular phosphorylation. The gene encoding this protein is 17 kb long and contains 17 exons. The interaction of ligand and its receptor on the cell membrane can induce the receptor dimerization after cytokines stimulation. The receptor and its coupled JAK kinases can then be activated via tyrosine phosphorylation. Meanwhile, the activated SH2 domain of SHP1 is able to catalyze JAKs or to induce tyrosine dephosphorylation of other tyrosine kinases (such as Src and c-fms). This induces a stop or a decrease in the kinase activity, negatively regulates cellular signal transduction, and inhibits cell proliferation [6, 7, 15–23]. Recent studies showed that SHP1 regulates cell cycle, proliferation and tumor progression by modulating cell cycle machinery through cyclin-dependent kinase 2 (CDK2), p27 and CyclinD1 . In addition, the inhibition of SHP1 in prostate cancer cells have been shown to induce G0/G1 phase cell cycle arrest and to change some cell cycle machinery, such as down-regulation of p27, CDK2 and CDK6 . Taken together, SHP1 is well-known to be associated with cell cycle regulation.
We hypothesized that SHP1 might affect the radiosensitivity of NSCLC by modulating cell cycle. Thus, SHP1 might serve as a potential target for regulating the radioresistance of NSCLC. In this study, we first established an A549 radioresistant subtype cell line (A549S1). We further demonstrated the phenomenon of G0/G1 and S phase arrest in this cell line, which was demonstrated by the data showing an increase and a decrease in the proportion of cells in the S and G0/G1 phase, respectively. Meanwhile, we demonstrated that the cellular levels of SHP1, CDK4 and CylinD1 in this cell line were increased, while the level of p16 was significantly decreased. Finally, the inhibition of SHP1 expression in A549S1 cells up-regulated their radiosensitivity and induced G0/G1 phase arrest. Taken together, our results provide the molecular basis for NSCLC radioresistance that can be leveraged in order to unravel the theoretical basis for improving the radiotherapy effectiveness in NSCLC.
The RPMI-1640 and G418 culture medium were purchased from Gibco (GIBCO, Invitrogen Inc., Carlsbad, CA, USA). Fetal bovine serum (FBS) was purchased from Hangzhou Sijiqing Biological Engineering Materials Co., Ltd. (Hangzhou, China). Trypsin, propidium (PI) and RNA enzyme were from Sigma (St. Louis, MO, USA). Lipofectamine 2000, Trizol, OPTI-MEM I and MMLV reverse transcriptase were from Invitrogen (Carlsbad, CA, USA). Taq DNA polymerase and Oligo dT primers were from Invitrogen (Carlsbad, CA, USA). dNTPs and DNA/protein molecular weight standards were purchased from Fermentas Inc. (Thermo Fisher Scientific, Waltham, MA, USA). Protein lysis buffer and BCA protein assay kit were from the Beyotime Institute of Biotechnology (Wuhan, China). Protease inhibitors were from Roche (Basel, Switzerland). Rabbit anti-human SHP-1, SHP-2, p16, CDK4 and Cylin D1 monoclonal antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). The rabbit anti-human GAPDH antibody was from Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA). HRP-conjugated goat anti-rabbit secondary antibody IgG was purchased from Beijing Zhongshan Golden Bridge Co., Ltd. (Beijing, China). The ECL chemiluminescence reagent was from Pierce Chemicals (Rockford, IL, USA).
The human NSCLC cell line A549 was purchased from the American Type Culture Collection (ATCC). Cells were cultured in RPMI1640 medium containing 10% FBS, 100 IU penicillin and 100 μg/mL streptomycin and incubated at 37°C and in a 5% CO2 humidified incubator.
Establishment of the NSCLC radioresistant subtype cell line
The A549S1 NSCLC radioresistant subtype cell line was established as previously reported . Briefly, 6 MV ionizing radiations from a Siemens Primus H high-energy linear accelerator (Siemens, Erlangen, Germany) was used for irradiation of A549 cells at a field of 10 × 10 cm and a SSD of 100 cm, with an absorption dosage of 200 cGy/min. A thick 1.5-cm block was used to cover culture bottles for compensation. Parental A549 cells in the logarithmic growth phase were randomly divided into two groups (n = 3 per group). Each group received an irradiation dose of 6 or 2 Gy/fraction, which was repeated for five or fifteen fractions, respectively. After each fraction, the cells were passaged at the end of the logarithmic growth phase. Two cell clones were obtained from the surviving cells, which were named A549S1 and A549S2, and were used to investigate the radiosensitivity for three months without irradiation.
The construction of PGCsiRNA
siRNA sequences for SHP1 gene
siRNA sequences (5’-STEM-Loop-STEM-3′)
Transcriptional start site
Measurement of mRNA transcription by Real-time RT-PCR
Total RNA was extracted from the pGCsiRNA1907, pGCsiRNA774 and pGCsiRNA-NC cell groups using Trizol, according to the manufacturer’s instructions. RNA purity was assessed by A260/A280. Total RNA (1 μg) was reverse transcribed into cDNA using primer Oligo dT and MMLV reverse transcriptase (Promega, CA, USA). Specific mRNA quantification was performed by real-time PCR using SYBR® Green master mixes (Life Technologies, NY, USA) in ABI PRISM® 7900HT Sequence Detection System (Life Technologies), according to the manufacturer’s instructions. SHP-1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were designed using the Primer Premier 5.0 software. The gene-specific primers used were: SHP-1 forward: 5′-AGA AGC AGG AGT CCG AGG AT-3′, reverse: 5′- GCT GTG GTC AAA GGG GAG AA -3′; GADPH forward: 5′- CTC CTC CTG TTC GAC AGT CAG C -3′, reverse: 5′- CCC AAT ACG ACC AAA TCC GTT -3′. PCR reactions involved 45 cycles of 95°C for 30 s, 60°C for 60 s. The Ct value was defined as the number of PCR cycles in which the fluorescence signal exceeded the detection threshold value. First, ΔCt = Ct Gene - Ct GAPDH. Then, ΔΔCt = ΔCt treated - ΔCt control. Lastly, 2-ΔΔCt was calculated to represent the relative mRNA expression of target genes. GAPDH was used as internal control.
Cell lysates were prepared using the protein lysis buffer, according to the manufacturer’s instructions. Following extraction, protein concentration was determined by a BCA assay. A total of 25 μg protein from each sample was loaded into a 10% SDS-PAGE, followed by a transfer to PVDF membrane (Millipore Corporation, Billerica, MA). Membranes were blocked with 5% non-fat dry milk overnight. They were then incubated with rabbit anti-human SHP1, SHP2, p16, CDK4, GAPDH and CylinD1 antibodies at 4°C overnight. After washing, membranes were incubated with horseradish peroxidase-conjugated goat anti- rabbit IgG for 1 h. The ECL chromogenic agent was used to develop the membranes and the optical density of the bands was analyzed using the Image J software (National Institutes of Health, Bethesda, MD, USA).
Construction and identification of A549 cells stably transfected plasmids
One day before transfection, A549S1 cells were trypsin-digested and counted. Cells were plated in 6-well plates, and the transfection was conducted when they reached an 80-90% confluence. Cells were plated in 2 ml of DMEM medium containing serum without antibiotics. A total of 2 μg pGCsiRNA1907 was diluted in 250 μl of OPTI-MEM I medium, mixed gently and left at room temperature for 5 min. In the meantime, 5 μl of Lipofectamine 2000 was diluted in 250 μl of OPTI-MEM I medium, mixed gently and left at room temperature for 5 min. The diluted pGCsiRNA1907 and Lipofectamine2000 (250 μl of each) were gently mixed and left at room temperature for 20 min. The mixture was then transferred to the cell culture plates, and mixed gently. After 24 h of culture in a CO2 incubator at 37°C, cells were diluted, passaged into three culture plates (10 cm diameter) and treated with the G418 antibiotic (500 μg/ml) after 24 h. Empty vector and blank controls without plasmid DNA were used as negative controls.
Following two weeks of culture in DMEM medium containing G418 (500 μg/ml) and 10% FBS, the formation of monoclonal cell masses tranfected with target genes or empty vector was observed. However, all cells without plasmid DNA transfection died. Monoclonal cell masses were digested with trypsin and transferred into 6-well plates (2 ml DMEM mediun containing 500 μg/ml of G418 and 10% of FBS were added to each plate in advance). Between 12 and 24 clone cell masses were picked up from each transfection system. Cells were passaged into a T25 flask upon reaching an 80-90% confluence and collected upon reaching a 100% confluence. Half of the cells were used to extract RNA for RT-PCR analysis of the target gene expression and the other half was used for cryopreservation. Cells with expression of the target gene were cultured for three months using a compressing model and were stably transfected with the plasmid or empty vector; they were named A549S1/siSHP1 and A549S1/siMock, respectively.
Clone formation assay for cell survival fraction analysis
A single cell suspension was prepared from the cells in their logarithmic growth phase using 0.25% trypsin for digestion. Cells were seeded in 6-well plates and received a single-dose irradiation of 0, 2, 4, 6, 8 and 10 Gy after a 12 h culture adherence. Two weeks later, cells were treated with 4% paraformaldehyde and were stained using Giemsa. Cell survival fraction (SF) was calculated based on the following formula: SF = colony numbers in experimental group/(Plating number × Plating efficiency (PE)). PE = (colony numbers in control group/Plating efficiency (PE)) × 100%. Cell survival curve was obtained by the single-hit multi-target model (S = l-(1-e-D0/D)N) using Sigma Plot 2001 Demo version. The parameters of cell survival fraction, mean lethal dose value (D0), quasithreshold dose (Dq) and extrapolation number (N) were calculated with a 2 cGy irradiation dose (SF2). Higher values of SF2, D0, Dq and N indicated a higher radiosensitivity.
Cell cycle analysis by flow cytometry
A single cell suspension was made from cells in their logarithmic growth phase using 0.25% trypsin for digestion. Cells were placed in precooled 70% ethanol at −20°C for fixation overnight. Cells were then washed in PBS and digested using RNA enzyme. PI was added into the cells at a final concentration of approximately 60 μg/ml. Cells were incubated in the dark, and the cell cycle phases were examined by flow cytometry (Beckman, USA). All experiments were conducted in triplicate.
Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Significant differences between the groups were determined by the Student’s t-test. A P-value <0.05 was considered to be statistically significant (P < 0.05).
Radiosensitivity changes in A549S1 and A549S2 cells
Radiosensitivity parameters of different cell lines
Radiosensitivity of A549 and A549S1 cell lines following a three-month culture
Radiosensitivity parameters of different cell lines after three months of culture
Cell cycle changes in A549, A549S1 and A549S2 cell lines
SHP1, SHP2, p16, CDK4 and Cyclin D1 protein levels changes in A549, A549S1 and A549S2 cells
Efficiency of SHP1 siRNA in pGCsiRNA774 and pGCsiRNA1907 plasmids in A549S1 cells at mRNA and protein levels
Effects of SHP1 siRNA on the expression of cell cycle-related proteins
Stable SHP1 siRNA expression increased the radiosensitivity of A549S1 cells
Radiosensitivity parameters of A549S1/siSHP1 and A549S1/siMock cells
Effect of stable SHP1 siRNA inhibition on cell cycle
It has been reported that a radioresistant phenotype in cells can be changed to a radiosensitive one during fractionated radiotherapy regimens, which could be beneficial for increasing treatment efficiency in destroying tumor cells. However, if the cell cycle does not change accordingly and effectively, this could lead to radioresistance. Ionizing radiations can induce changes in cell cycle progression, such as G1 and G2 phases arrest. Moreover, the arrest time is dependent on the intrinsic cell’s radiosensitivity, which is the key event for the cells to check the authenticity and integrity of their genetic material, and to repair damages. However, the detailed molecular mechanisms for this process are still unknown . In this study, we investigated the relationship between radiosensitivity and cell cycle in NSCLC, as well as its molecular mechanisms.
We successfully established a NSCLC radioresistant cell line (A549S1 and S549S2) using two fractionated irradiation methods. However, the best irradiation dose and fractionation regimen for the generation of radiation-induced resistance are still controversial. Previous studies demonstrated that radioresistant subtype cell lines were rapidly established by 3–5 fractions of 6 cGy . Thus, in this study, the A549S1 cell line was established by setting the irradiation dose at 6 cGy/fraction for 5 fractions. On the other hand, the control cell line A549S2 was established by the general fractionated irradiation method (2 cGy/fraction for 15 fractions). Results of this present study showed that the radiosensitivity of A549S1 was significantly decreased compared with A549 cells.
Previous studies have shown that there might be two reasons for the formation of radioresistant cells, including radiation-induced cell screening and cell mutation [26, 27]. Indeed, radiosensitive cells are easily destroyed by radiations, while radioresistant cells survive in the harsh irradiated environment. In addition, radiations stimulate structural changes at the cellular and molecular levels, some of which induce a radioresistant phenotype by inducing mutations. Cells radiosensitivity is different with different cell cycle phases. For example, cells in S, G0/G1 and G2/M phases are radioresistant, relatively radiosenstive and radiosenstive, respectively .
Results from this study showed that the proportions of cells in the S and G0/G1 phases were significantly increased and decreased, respectively, in A549S1 cells compared with A549 cells. The proportions of cells in G2/M phase were not changed in these two cell lines, suggesting an S phase arrest in A549S1 cells. Moreover, the proportion of cells in each phase did not change in A549S2 cells. Thus, we hypothesized that the radioresistance of A549S1 was caused by changes in cell cycle progression. Our data confirmed that high-dose hypofractionated irradiation induced the formation of radioresistance in cells in vitro, which was related to the cell cyle in the tumor cells. These results are in line with previous findings [25, 28]. In the meantime, protein expression levels of SHP1, CDK4 and CylinD1 were increased, while p16 expression level was decrased in A549S1 cells, suggesting an important role of these factors in radiosensitivity and cell cycle progression. Due to the fact that SHP2 expression was not changed in A549S1 cells compared with A549 cells, we investigated the effect of SHP1 siRNA on the regulation of radiosensitivity, as well as on p16, Cyclin D1 and CDK4 expression.
SHP-1 is closely related to the regulation of cell cycle. Indeed, a number of cellular proteins (such as protein kinase C, SHP1, Rac, Rho and Scr) are activators of the PI3K/Akt pathway, which has been demonstrated to play a crucial role in cell cycle progression [17, 18]. Activation of the PI3K/Akt pathway increases Cyclin D1 and CDK4, and decreases p16 [17, 18]. Cyclin D1 is an important regulator in the transformation of G1 to S phase. Normally, Cyclin D1 can bind with CDK4 to form a complex promoting Rb phosphorylation and stimulating cells transition from G1 into S phase. p16 is a tumor suppressor gene, which causes G0/G1 phase cell arrest by inhibiting Rb phosphorylation via p16 and Cyclin D1 competitory binding to CDK4. p16, Cyclin D1 and CDK4 are cell cycle regulatory factors, and their gene mutations or protein abnormalities are closely related to tumorigenesis, tumor development and progression in a variety of tumors . However, even if these proteins play a clear role in tumorigenesis, the exact relationship between SHP1 and cell cycle-related proteins (Cyclin D1, CDK4 and p16) and its function in NSCLC or A549S1 cells is still unknown. Nevertheless, our results show that SHP1 kncokdown using siRNA increases p16 expression and decreases CDK4 and Cyclin D1 expressions, which may be mediated by the PI3K/Akt pathway, but how depletion of SHP1 results in an increase in p16 levels need to be further studied.
Our results showed that a stable SHP1 siRNA can induce a higher radiosensitivity in A549S1 cells. Compared with A549S1/siMock cells, the proportions of cells in S and G0/G1 phases were significantly decreased and increased in A549S1/siSHP1cells, respectively. Meanwhile, the inhibition of SHP1 induced p16 up-regulation, and CDK4 and CylinD1 down-regulation. These data suggested that stable inhibition of SHP1 increased the radiosensitivity by affecting the expression of CDK4, CylinD1 and p16 (cell cycle related proteins), thus delaying the G1/S checkpoint in NSCLC cells. Our results are supported by the recent observations indicating that SHP1 supression induces G1/S arrest in prostate cancer cells .
In summary, we observed that SHP-1 attenuated the radiosensitivity of NSCLC cells through affecting cell cycle induced by cell cycle-related proteins such as CDK4, CylinD1 and p16. These findings could potentially increase our understanding of the molecular mechanisms involved in this process, and could identify potential targets to promote the efficacy of radiotherapy in NSCLC.
This study was supported by a grant from the Hubei Provincial Science Foundation (2012FFB02324).
- Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55: 74-108. 10.3322/canjclin.55.2.74View ArticlePubMedGoogle Scholar
- Le Pechoux C: Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist 2011, 16: 672-681. 10.1634/theoncologist.2010-0150View ArticlePubMedPubMed CentralGoogle Scholar
- Lee S, Lim MJ, Kim MH, Yu CH, Yun YS, Ahn J, Song JY: An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med 2012, 53: 807-816. 10.1016/j.freeradbiomed.2012.05.038View ArticlePubMedGoogle Scholar
- Provencio M, Sanchez A, Garrido P, Valcarcel F: New molecular targeted therapies integrated with radiation therapy in lung cancer. Clin Lung Cancer 2010, 11: 91-97. 10.3816/CLC.2010.n.012View ArticlePubMedGoogle Scholar
- Schuurbiers OC, Kaanders JH, van der Heijden HF, Dekhuijzen RP, Oyen WJ, Bussink J: The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J Thorac Oncol 2009, 4: 761-767. 10.1097/JTO.0b013e3181a1084fView ArticlePubMedGoogle Scholar
- Zhang Y, Hagedorn CH, Wang L: Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta 1812, 2011: 893-908.Google Scholar
- Mittal Y, Pavlova Y, Garcia-Marcos M, Ghosh P: Src homology domain 2-containing protein-tyrosine phosphatase-1 (SHP-1) binds and dephosphorylates G(alpha)-interacting, vesicle-associated protein (GIV)/Girdin and attenuates the GIV-phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway. J Biol Chem 2011, 286: 32404-32415. 10.1074/jbc.M111.275685View ArticlePubMedPubMed CentralGoogle Scholar
- Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009,28(Suppl 1):S24-S31.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu Y, Liu L, Qiu X, Liu Z, Li H, Li Z, Luo W, Wang E: CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells. PLoS One 2012, 7: e33262. 10.1371/journal.pone.0033262View ArticlePubMedPubMed CentralGoogle Scholar
- Salani B, Maffioli S, Hamoudane M, Parodi A, Ravera S, Passalacqua M, Alama A, Nhiri M, Cordera R, Maggi D: Caveolin-1 is essential for metformin inhibitory effect on IGF1 action in non-small-cell lung cancer cells. FASEB J 2012, 26: 788-798. 10.1096/fj.11-192088View ArticlePubMedGoogle Scholar
- Galluzzo P, Bocchetta M: Notch signaling in lung cancer. Expert Rev Anticancer Ther 2011, 11: 533-540. 10.1586/era.10.158View ArticlePubMedPubMed CentralGoogle Scholar
- Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY, Jiang B: JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 2011, 73: 366-374. 10.1016/j.lungcan.2011.01.002View ArticlePubMedGoogle Scholar
- Peng L, Ning J, Meng L, Shou C: The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 2004, 130: 521-526.View ArticlePubMedGoogle Scholar
- Hatate K, Yamashita K, Hirai K, Kumamoto H, Sato T, Ozawa H, Nakamura T, Onozato W, Kokuba Y, Ihara A, et al.: Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9. Oncol Rep 2008, 20: 737-743.PubMedGoogle Scholar
- Beyaert R: SHP works a double shift to control TLR signaling. Nat Immunol 2011, 12: 725-727. 10.1038/ni.2075View ArticlePubMedGoogle Scholar
- Prasad S, Pandey MK, Yadav VR, Aggarwal BB: Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila) 2011, 4: 1084-1094. 10.1158/1940-6207.CAPR-10-0340View ArticleGoogle Scholar
- Lopez-Ruiz P, Rodriguez-Ubreva J, Cariaga AE, Cortes MA, Colas B: SHP-1 in cell-cycle regulation. Anticancer Agents Med Chem 2011, 11: 89-98. 10.2174/187152011794941154View ArticlePubMedGoogle Scholar
- Rodriguez-Ubreva FJ, Cariaga-Martinez AE, Cortes MA, Romero-De Pablos M, Ropero S, Lopez-Ruiz P, Colas B: Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery. Oncogene 2010, 29: 345-355. 10.1038/onc.2009.329View ArticlePubMedGoogle Scholar
- Yu Z, Maoui M, Zhao ZJ, Li Y, Shen SH: SHP-1 dephosphorylates 3BP2 and potentially downregulates 3BP2-mediated T cell antigen receptor signaling. FEBS J 2006, 273: 2195-2205. 10.1111/j.1742-4658.2006.05233.xView ArticlePubMedGoogle Scholar
- Zhang J, Shen B: SHP limits TLR signaling, an inducible transcriptional corepressor. Cell Mol Immunol 2011, 8: 445-446. 10.1038/cmi.2011.31View ArticlePubMedPubMed CentralGoogle Scholar
- Iype T, Sankarshanan M, Mauldin IS, Mullins DW, Lorenz U: The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells. J Immunol 2010, 185: 6115-6127. 10.4049/jimmunol.1000622View ArticlePubMedPubMed CentralGoogle Scholar
- Biskup C, Bohmer A, Pusch R, Kelbauskas L, Gorshokov A, Majoul I, Lindenau J, Benndorf K, Bohmer FD: Visualization of SHP-1-target interaction. J Cell Sci 2004, 117: 5165-5178. 10.1242/jcs.01397View ArticlePubMedGoogle Scholar
- Zhu Z, Oh SY, Cho YS, Zhang L, Kim YK, Zheng T: Tyrosine phosphatase SHP-1 in allergic and anaphylactic inflammation. Immunol Res 2010, 47: 3-13. 10.1007/s12026-009-8134-5View ArticlePubMedPubMed CentralGoogle Scholar
- Shi D, Shi G, Huang G, Zhang J, Lartigau E: Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma. J Exp Clin Cancer Res 2009, 28: 72. 10.1186/1756-9966-28-72View ArticlePubMedPubMed CentralGoogle Scholar
- Lieberman HB, Hopkins KM: Schizosaccharomyces malidevorans and Sz. octosporus homologues of Sz. pombe rad9, a gene that mediates radioresistance and cell-cycle progression. Gene 1994, 150: 281-286. 10.1016/0378-1119(94)90438-3View ArticlePubMedGoogle Scholar
- Pearce AG, Segura TM, Rintala AC, Rintala-Maki ND, Lee H: The generation and characterization of a radiation-resistant model system to study radioresistance in human breast cancer cells. Radiat Res 2001, 156: 739-750. 10.1667/0033-7587(2001)156[0739:TGACOA]2.0.CO;2View ArticlePubMedGoogle Scholar
- Wei K, Kodym R, Jin C: Radioresistant cell strain of human fibrosarcoma cells obtained after long-term exposure to x-rays. Radiat Environ Biophys 1998, 37: 133-137. 10.1007/s004110050106View ArticlePubMedGoogle Scholar
- Teyssier F, Bay JO, Dionet C, Verrelle P: Cell cycle regulation after exposure to ionizing radiation. Bull Cancer 1999, 86: 345-357.PubMedGoogle Scholar
- Kusume T, Tsuda H, Kawabata M, Inoue T, Umesaki N, Suzuki T, Yamamoto K: The p16-cyclin D1/CDK4-pRb pathway and clinical outcome in epithelial ovarian cancer. Clin Cancer Res 1999, 5: 4152-4157.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.